Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.58 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472420 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP2D6TMEM97TP53 | |
| Hydrochloric Acid SCHEMBL2727622 | 0.98 | SIGMAR1 (0.97) | SIGMAR1CYP1A2CYP2D6TMEM97TP53 | |
| Hydrochloric Acid SCHEMBL30570469 | 0.98 | SIGMAR1 (0.97) | SIGMAR1CYP1A2CYP2D6TMEM97TP53 | |
| SCHEMBL7528803 | 0.88 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP2D6TMEM97TP53 | |
| SCHEMBL7529966 | 0.85 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP2D6TMEM97 | |
| SCHEMBL5804316 | 0.84 | SIGMAR1 (0.93) | SIGMAR1CYP1A2CYP2D6TMEM97TP53 | |
| SCHEMBL13202506 | 0.84 | SIGMAR1 (0.73) | SIGMAR1CYP1A2CYP2D6TMEM97 | |
| SCHEMBL4173183 | 0.82 | SIGMAR1 (0.78) | SIGMAR1CYP1A2CYP2D6TMEM97CYP3A4 | |
| SCHEMBL2291008 | 0.81 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP2D6TMEM97 | |
| Bromide SCHEMBL4168906 | 0.81 | SIGMAR1 (0.76) | SIGMAR1CYP1A2CYP2D6TMEM97CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256720-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-09-13 | — | — | US | claimed |
| EP-1781272-B1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA | ESTEVE LABOR DR (ES) | 2017-09-06 | — | — | EP | claimed |
| WO-2010015040-A1 | THERAPY AND PREVENTION OF TDP-43 PROTEINOPATHY | POWMRI LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1781272-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-09 | — | — | EP | claimed |
| WO-2006027223-A1 | USE OF PIPERAZINE DERIVATIVES AND ANALOGUES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-16 | — | — | WO | claimed |
| EP-1634598-A1 | Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-15 | — | — | EP | claimed |
| WO-2006010587-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-02 | — | — | WO | claimed |
| WO-2025031979-A1 | USE OF RIMCAZOLE TO TREAT CANCER | KYREXA LTD (GB) | 2025-02-13 | — | — | WO | disclosed |
| WO-2022062991-A1 | INDOLE DERIVATIVES AND USE THEREOF | 苏州恩华生物医药科技有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-20220031706-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | UNIVERSITY OF LEEDS (GB) | 2022-02-03 | — | — | US | disclosed |
| EP-3308782-B1 | SIGMA-RECEPTOR BINDING AGENT | TOYAMA CHEMICAL CO LTD (JP) | 2022-01-19 | — | — | EP | disclosed |
| US-20210379016-A1 | THERAPEUTICS AND METHODS OF TREATMENT OF ANGIOTENSIN-CONVERTING ENZYME 2 ASSOCIATED CONDITIONS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2021-12-09 | — | — | US | disclosed |
| WO-2006010587-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005079767-A2 | MEANS FOR MODULATION OF THE EFFECTS OF OPIOID-LIKE SUBSTANCES | Universitätsklinikum Münster (DE) | 2005-09-01 | — | — | WO | disclosed |
| US-20040019060-A1 | Sigma receptor ligands and their medical uses | SPRUCE BARBARA ANN (GB) | 2004-01-29 | — | — | US | disclosed |
| EP-1267875-A1 | SIGMA RECEPTOR LIGANDS AND THEIR MEDICAL USES | Spruce, Barbara (GB) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074359-A1 | SIGMA RECEPTOR LIGANDS AND THEIR MEDICAL USES | SPRUCE BARBARA (GB) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019060-A1 | Sigma receptor ligands and their medical uses | TMEM97, SIGMAR1, GPR119 | SIGMAR1 2/4885CYP1A2 451/4885CYP2D6 1025/4885 |
| US-20210379016-A1 | THERAPEUTICS AND METHODS OF TREATMENT OF ANGIOTENSIN-CONVERTING ENZYME 2 ASSOCIATED CONDITIONS | ACE2, ACE, AGTR2 | SIGMAR1 10/4885CYP1A2 67/4885CYP2D6 79/4885 |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | SIGMAR1 4/4885CYP1A2 3407/4885CYP2D6 3345/4885 |
| US-20220031706-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | TRPC1, TRPC7, TRPC4 | SIGMAR1 1765/4885CYP1A2 1875/4885CYP2D6 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.